The Economics of Reproducibility in Preclinical Research
Article Introductory Summary:
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative prevalence of irreproducible preclinical research exceeds 50% in the United States alone. This article discusses the main causes of low reproducibility: study design, biological reagents and reference materials, laboratory protocols, and data analysis and reporting and outlines a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.